Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT00073866
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Combining celecoxib with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan and docetaxel when given together with celecoxib and to see how well they work in treating patients with advanced non-small cell lung cancer.

Key Dates

Start date
Jun 30, 2003
Status verified
Jul 2012
Primary completion
Dec 31, 2004
Completion
Dec 31, 2004

Study Design

Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicagoIllinois60611-3013-
Evanston Northwestern Health Care - Evanston HospitalEvanstonIllinois60201-
Silver Cross HospitalJolietIllinois60432-

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Robert H. Lurie Comprehensive Cancer Center at Northwestern University· Chicago, ILEvanston Northwestern Health Care - Evanston Hospital· Evanston, ILSilver Cross Hospital· Joliet, IL

Related Studies